0      0

ENGLISH - Continuous Manufacturing of Biologics

‐ Dec 7, 2021 12:10pm

Continuous Manufacturing (CM) of biologics has been a hot topic for recent years because it has a potential for improving the efficiency, agility, and flexibility of drug substance and drug product manufacturing. In addition, ICH Q13 reached to step 2 on July 27, and is expected to progress to step 4 next year. This session will discuss ICH Q13 updates and perspectives from regulators and industry for CM of biologics.

Session Chair(s):


Panel Member(s):

You must be logged in and own this session in order to post comments.